{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:30:01Z","timestamp":1775493001513,"version":"3.50.1"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.2169\/internalmedicine.2233-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:38:27Z","timestamp":1548974307000},"page":"1549-1555","source":"Crossref","is-referenced-by-count":15,"title":["Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for &lt;i&gt;Helicobacter pylori&lt;\/i&gt; Eradication"],"prefix":"10.2169","volume":"58","author":[{"given":"Maho","family":"Kusunoki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"},{"name":"Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Ishitobi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Fukuba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Komazawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Shizuku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Shimane University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori<\/i> eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446, 2016.","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"2","unstructured":"2. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on <i>Helicobacter pylori<\/i> eradication. Aliment Pharmacol Ther 46: 106-114, 2017."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of <i>Helicobacter pylori<\/i>. Digestion 94: 240-246, 2016.","DOI":"10.1159\/000454762"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of <i>Helicobacter pylori<\/i>. World J Gastrointest Pharmacol Ther 7: 550-555, 2016.","DOI":"10.4292\/wjgpt.v7.i4.550"},{"key":"5","unstructured":"5. Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multicenter cohort study on <i>Helicobacter pylori<\/i> eradication. Intern Med 56: 1277-1285, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Haruma K, Kamada T, Kawaguchi H, et al. Effect of age and <i>Helicobacter pylori<\/i> on gastric acid secretion. J Gastroenterol Hepatol 15: 277-283, 2000.","DOI":"10.1046\/j.1440-1746.2000.02131.x"},{"key":"7","unstructured":"7. United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA\/P\/WP\/248."},{"key":"8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0028-1098086","volume":"1","author":"K Kimura","year":"1969","unstructured":"8. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1: 87-97, 1969.","journal-title":"Endoscopy","ISSN":"https:\/\/id.crossref.org\/issn\/0013-726X","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Scott D, Weeks D, Melchers K, Sachs G. The life and death of <i>Helicobacter pylori<\/i>. Gut 43 (suppl 1): S56-S60, 1998.","DOI":"10.1136\/gut.43.2008.S56"},{"key":"10","unstructured":"10. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for <i>Helicobacter pylori<\/i> eradication. Aliment Pharmacol Ther 28: 868-877, 2008."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lee JY, Kim N, Kim MS, et al. Factors affecting \ufb01rst-line triple therapy of <i>Helicobacter pylori<\/i> including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 59: 1235-1243, 2014.","DOI":"10.1007\/s10620-014-3093-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of <i>Helicobacter pylori<\/i> strains in Japan between 2002 and 2005. J Clin Microbiol 45: 4006-4010, 2007.","DOI":"10.1128\/JCM.00740-07"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Perez Aldana L, Kato M, Nakagawa M, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary <i>Helicobacter pylori<\/i> resistance. Helicobacter 7: 306-309, 2002.","DOI":"10.1046\/j.1523-5378.2002.00096.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335: 231-238, 2010.","DOI":"10.1124\/jpet.110.170274"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study. Aliment Pharmacol Ther 42: 719-730, 2015.","DOI":"10.1111\/apt.13325"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of <i>Helicobacter pylori<\/i> in Japan: a multi-generational comparison. Helicobacter 19: 214-220, 2014.","DOI":"10.1111\/hel.12124"},{"key":"17","unstructured":"17. Nomura S, Ida K, Terao S, et al. Research Group for Establishment of Endoscopic Diagnosis of Chronic Gastritis Endoscopic diagnosis of gastric mucosal atrophy: multicenter prospective study. Dig Endosc 26: 709-719, 2014."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nomura S, Terao S, Adachi K, et al. Endoscopic diagnosis of gastric mucosal activity and inflammation. Dig Endosc 25: 136-146, 2013.","DOI":"10.1111\/j.1443-1661.2012.01357.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Osawa H, Kita H, Ohnishi H, et al. <i>Helicobacter pylori<\/i> eradication induces marked increase in H<sup>+<\/sup>\/K<sup>+<\/sup>-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut 55: 152-157, 2006.","DOI":"10.1136\/gut.2005.066464"},{"key":"20","unstructured":"20. Tucci A, Poli L, Biasco G, et al. <i>Helicobacter pylori<\/i> infection and gastric function in patients with fundic atrophic gastritis. Dig Dis Sci 46: 1573-1583, 2001."},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Kinoshita Y, Kawanami C, Kishi K, et al. <i>Helicobacter pylori<\/i> independent chronological change in gastric acid secretion in the Japanese. Gut 41: 452-458, 1997.","DOI":"10.1136\/gut.41.4.452"},{"key":"22","unstructured":"22. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and <i>Helicobacter pylori<\/i>. Yale J Biol Med 69: 301-316, 1996."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among <i>Helicobacter pylori<\/i> isolates from Japan. Antimicrob Agents Chemother 44: 2214-2216, 2000.","DOI":"10.1128\/AAC.44.8.2214-2216.2000"},{"key":"24","unstructured":"24. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of <i>Helicobacter pylori<\/i> antibiotic resistance. Aliment Pharmacol Ther 43: 514-533, 2016."},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of <i>Helicobacter pylori<\/i> in Japanese peptic ulcer patients. Helicobacter 6: 254-261, 2001.","DOI":"10.1046\/j.1523-5378.2001.00037.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2233-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:13:36Z","timestamp":1559362416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/11\/58_2233-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2233-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}